Target intelligence / Profile preview

Claudin domain-containing protein 1 (CLDND1)

Target
CLDND1
Molecular classification
Other (Tight junction protein), Membrane protein
01

Overview

Claudin domain-containing protein 1 (CLDND1) is a transmembrane protein belonging to the claudin family and is involved in the formation and regulation of tight junctions in various tissues[1][5][7]. These junctions are critical structures that control paracellular barrier permeability and help maintain cell–cell adhesion, particularly in the central nervous system and endothelium[1][6]. In the brain, CLDND1 expression is important for vascular barrier integrity, with its downregulation leading to increased endothelial permeability following injury[1]. CLDND1 is dynamically regulated by physiological and environmental factors, including transcriptional control by RORα and MZF1, and post-transcriptional regulation by microRNAs[1]. In immune cells, particularly CD4+ T-cells, CLDND1 may function as a negative regulator of proliferation or induce cell death, suggesting a role in immune tolerance and possibly in autoimmune disease[3]. Its expression and regulation have been implicated in cancer cell survival, cerebrovascular disease, and immune modulation, but it is not yet considered a direct therapeutic target nor are there known drugs targeting it specifically[1][3][7].

Other names
Claudin-25Membrane protein GENX-3745C3orf4HSPC174PSEC0054UNQ2511/PRO6000Z38CLDN-25GENX-3745claudin domain containing 1 proteinclaudin-25membrane protein GENX-3745
02

Biological functions

Tight junction formationCell–cell adhesionRegulation of vascular permeabilityNegative regulation of T-cell proliferationInduction of cell death (context dependent)Cell survival
03

Disease associations

CancerCerebrovascular disease (stroke)Rheumatoid arthritisCardiometabolic diseaseOther (possibly immune tolerance and autoimmune disease)
04

Safety considerations

Disruption can increase vascular permeability or compromise barrier function, with a potential role in neurovascular injuryPossible immune regulation concerns based on T-cell studies
05

Biomarkers

Potential marker for cerebrovascular injury and rheumatoid arthritis (not clinically validated)

Beyond the preview

Go deeper on Claudin domain-containing protein 1 (CLDND1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Claudin domain-containing protein 1 (CLDND1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call